Belinda Ann Di Bartolo

List of Publications by Year in Descending Order

34 papers	604 citations	13 h-index	24 g-index
35 ext. papers	729 ext. citations	5.2 avg, IF	3.86 L-index

#	Paper	IF	Citations
34	HDL Improves Cholesterol and Glucose Homeostasis and Reduces Atherosclerosis in Diabetes-Associated Atherosclerosis. *Journal of Diabetes Research*, **2021**, 2021, 6668506	3.9	2
33	Omega-3 fatty acids ameliorate vascular inflammation: A rationale for their atheroprotective effects. *Atherosclerosis*, **2021**, 324, 27-37	3.1	9
32	Bench-to-Bedside in Vascular Medicine: Optimizing the Translational Pipeline for Patients With Peripheral Artery Disease. *Circulation Research*, **2021**, 128, 1927-1943	15.7	4
31	FXYD1 Is Protective Against Vascular Dysfunction. *Hypertension*, **2021**, 77, 2104-2116	8.5	
30	The novel P2X7 receptor antagonist PKT100 improves cardiac function and survival in pulmonary hypertension by direct targeting of the right ventricle. *American Journal of Physiology - Heart and Circulatory Physiology*, **2020**, 319, H183-H191	5.2	8
29	Single-Cell Immune Profiling in Coronary Artery Disease: The Role of State-of-the-Art Immunophenotyping With Mass Cytometry in the Diagnosis of Atherosclerosis. *Journal of the American Heart Association*, **2020**, 9, e017759	6	10
28	A "Western Diet" promotes symptoms of hepatic steatosis in spontaneously hypertensive rats. *International Journal of Experimental Pathology*, **2020**, 101, 152-161	2.8	2
27	Plaque Calcification: Do Lipoproteins Have a Role?. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2019**, 39, 1902-1910	9.4	22
26	Associations of ABCG1-mediated cholesterol efflux capacity with coronary artery lipid content assessed by near-infrared spectroscopy. *Cardiovascular Diagnosis and Therapy*, **2019**, 9, 310-318	2.6	4
25	Vasculogenic properties of adventitial Sca-1CD45 progenitor cells in mice: a potential source of vasa vasorum in atherosclerosis. *Scientific Reports*, **2019**, 9, 7286	4.9	12
24	Vascular calcification in response to pharmacological interventions **2019**, 181-189		
23	High-Density Lipoprotein Infusions. *Cardiology Clinics*, **2018**, 36, 311-315	2.5	1
22	Coronary arterial calcification: A review of mechanisms, promoters and imaging. *Trends in Cardiovascular Medicine*, **2018**, 28, 491-501	6.9	34
21	VEGFR2 is activated by high-density lipoproteins and plays a key role in the proangiogenic action of HDL in ischemia. *FASEB Journal*, **2018**, 32, 2911-2922	0.9	7
20	Highlights From Vascular Discovery: From Genes to Medicine Scientific Sessions 2018. *Journal of the American Heart Association*, **2018**, 7, e009470	6	
19	Translating Evidence of HDL and Plaque Regression. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 1961-1968	9.4	17
18	PCSK9 Inhibitors in Hyperlipidemia: Current Status and Clinical Outlook. *BioDrugs*, **2017**, 31, 167-174	7.9	11

17	Non-alcoholic fatty liver disease, vascular inflammation and insulin resistance are exacerbated by TRAIL deletion in mice. *Scientific Reports*, **2017**, 7, 1898	4.9	31
16	Anacetrapib as a potential cardioprotective strategy. *Drug Design, Development and Therapy*, **2017**, 11, 3497-3502	4.4	7
15	Infusional high-density lipoproteins therapies as a novel strategy for treating atherosclerosis. *Archives of Medical Science*, **2017**, 13, 210-214	2.9	4
14	Clinical trials with cholesteryl ester transfer protein inhibitors. *Current Opinion in Lipidology*, **2016**, 27, 545-549	4.4	12
13	Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond. *Archives of Medical Science*, **2016**, 12, 1302-1307	2.9	12
12	Insulin promotes vascular smooth muscle cell proliferation and apoptosis via differential regulation of tumor necrosis factor-related apoptosis-inducing ligand. *Journal of Diabetes*, **2016**, 8, 568-78	3.8	11
11	CETP Inhibition in CVD Prevention: an Actual Appraisal. *Current Cardiology Reports*, **2016**, 18, 43	4.2	12
10	Acute high-density lipoprotein therapies. *Current Opinion in Lipidology*, **2015**, 26, 521-5	4.4	2
9	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Promotes Angiogenesis and Ischemia-Induced Neovascularization Via NADPH Oxidase 4 (NOX4) and Nitric Oxide-Dependent Mechanisms. *Journal of the American Heart Association*, **2015**, 4,	6	38
8	TRAIL-deficiency accelerates vascular calcification in atherosclerosis via modulation of RANKL. *PLoS ONE*, **2013**, 8, e74211	3.7	43
7	Sp1, acetylated histone-3 and p300 regulate TRAIL transcription: mechanisms of PDGF-BB-mediated VSMC proliferation and migration. *Journal of Cellular Biochemistry*, **2012**, 113, 2597-606	4.7	35
6	The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. *Atherosclerosis*, **2011**, 217, 395-400	3.1	49
5	The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit. *Lipids in Health and Disease*, **2011**, 10, 224	4.4	23
4	Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. *Cardiovascular Research*, **2011**, 91, 537-45	9.9	32
3	TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. *Circulation Research*, **2010**, 106, 1061-71	15.7	64
2	Anti-inflammatory effects of apolipoprotein A-I in the rabbit. *Atherosclerosis*, **2010**, 212, 392-7	3.1	61
1	Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. *Free Radical Research*, **2009**, 43, 772-82	4	25